Disc Medicine, Inc.
IRON
$-0.22
Change (1 day)
$77.60
Year High
$25.60
Year Low
Categories
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
P/E ratio for Disc Medicine, Inc. (IRON)
P/E ratio as of 2023: -16.86
According to Disc Medicine, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.86. At the end of 2022 the company had a P/E ratio of -0.45.
P/E ratio history for Disc Medicine, Inc. from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -16.86 |
| 2022 | -0.45 |
| 2021 | -2.27 |
| 2020 | -10.46 |